Myriad Genetics (MYGN) Stock Overview
A molecular diagnostics and precision medicine company, develops molecular tests. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MYGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Myriad Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.32 |
| 52 Week High | US$8.59 |
| 52 Week Low | US$3.53 |
| Beta | 1.65 |
| 1 Month Change | -9.52% |
| 3 Month Change | 13.68% |
| 1 Year Change | 29.76% |
| 3 Year Change | -75.56% |
| 5 Year Change | -84.90% |
| Change since IPO | -1.02% |
Recent News & Updates
Narrative Update • Jul 09
MYGN: New Cancer Test Data And AI Initiatives Will Support A Balanced Outlook
Analysts trimmed their price outlook for Myriad Genetics, lowering the implied fair value estimate from $8.12 to $6.25 as they recalibrated assumptions around revenue growth, profit margins, and future P/E expectations following recent research updates. What’s in the News for Myriad Genetics Myriad Genetics reported new large scale meta analysis data for its Prolaris Biopsy Test in localized prostate cancer, showing that the combined clinical risk score was significantly prognostic for distant metastasis and prostate cancer specific mortality across multiple risk groups and treatment strategies, based on 14 studies with data from more than 8,000 patients (source: Clinical Genitourinary Cancer publication).
Narrative Update • Jun 25
MYGN: 2026 Turnaround Will Be Driven By Expanded Cancer Testing Reach
Analysts have trimmed their target on Myriad Genetics stock by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Myriad Genetics Expanded availability of the Precise MRD test to patients with breast, colorectal, and renal cancers in the U.S., targeting a population of more than 6 million individuals and providing personalized, whole genome sequencing based ctDNA monitoring across the cancer care continuum.Recent updates
Narrative Update • Jul 09
MYGN: New Cancer Test Data And AI Initiatives Will Support A Balanced Outlook
Analysts trimmed their price outlook for Myriad Genetics, lowering the implied fair value estimate from $8.12 to $6.25 as they recalibrated assumptions around revenue growth, profit margins, and future P/E expectations following recent research updates. What’s in the News for Myriad Genetics Myriad Genetics reported new large scale meta analysis data for its Prolaris Biopsy Test in localized prostate cancer, showing that the combined clinical risk score was significantly prognostic for distant metastasis and prostate cancer specific mortality across multiple risk groups and treatment strategies, based on 14 studies with data from more than 8,000 patients (source: Clinical Genitourinary Cancer publication).Narrative Update • Jun 25
MYGN: 2026 Turnaround Will Be Driven By Expanded Cancer Testing Reach
Analysts have trimmed their target on Myriad Genetics stock by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Myriad Genetics Expanded availability of the Precise MRD test to patients with breast, colorectal, and renal cancers in the U.S., targeting a population of more than 6 million individuals and providing personalized, whole genome sequencing based ctDNA monitoring across the cancer care continuum.
Narrative Update • Jun 08
MYGN: 2026 Revenue Outlook And Lowered Multiple Will Pressure Sentiment
Analysts have modestly reduced their price target on Myriad Genetics by $1, citing updated assumptions around revenue growth, profitability and future P/E multiples reflected in recent research, including the TD Cowen report. What's in the News Myriad plans to present extensive data on its Precise MRD test across multiple solid tumor types, including interim outcomes from the MONSTAR-SCREEN-3 study.Narrative Update • May 25
MYGN: 2026 Turnaround Execution And Cancer Testing Expansion Will Drive Upside
The analyst price target for Myriad Genetics has been reset from $16.06 to $10.00 as analysts factor in lower Street targets around $6, updated assumptions for revenue growth and profit margins, and a revised future P/E closer to 6.3x. Analyst Commentary Recent Street research has generally moved toward more cautious price targets around US$6, but there are still some constructive signals that matter if you are looking at Myriad Genetics through a valuation and execution lens.Narrative Update • Apr 21
MYGN: 2026 Turnaround And Pipeline Milestones Will Keep Sentiment Cautious
Analyst price targets on Myriad Genetics have moved slightly lower, with recent cuts to $6 from $8 and $6.50, as analysts wait for clearer evidence of progress on the turnaround plan, pipeline milestones, and improved growth and profitability before shifting their stance. Analyst Commentary Recent Street research reflects a cautious stance on Myriad Genetics, with bearish analysts trimming price targets and highlighting execution and growth risks despite some operational positives.Narrative Update • Apr 05
MYGN: 2026 Turnaround Execution And Pipeline Delivery Will Sustain Bearish Caution
Analysts have trimmed their price targets on Myriad Genetics to a range of $6 to $7, reflecting caution around the pace of the turnaround and the need for clearer progress on growth, profitability and pipeline execution before taking a more constructive stance. Analyst Commentary Recent research updates point to a cautious tone, with several bearish analysts trimming price targets into the US$6 to US$7 range and maintaining neutral ratings.Seeking Alpha • Mar 31
Myriad Genetics: SOTP Suggests The Company Is Undervalued
Summary Myriad Genetics, Inc. has grown from a mainly Hereditary Cancer business into a broader precision medicine company, but the market still values it at a low multiple because earnings, cash flow, and. The strongest part of the business is still the core Hereditary Cancer franchise, which has shown better resilience than other units through stronger volume trends and steadier operating performance. Even on a conservative sum-of-the-parts basis, the stock appears undervalued, with an estimated value of about $6.05 per share versus the current market price. Followed by portfolio simplification can bring further upside. Near-term catalysts in 2026, including HCT Precise MRD customer testing, the planned AI-enabled Prolaris launch, and continued cost discipline, could help narrow the valuation gap. Read the full article on Seeking AlphaNarrative Update • Mar 21
MYGN: Turnaround Execution In 2026 Will Drive Continued Cautious Sentiment
The Street’s blended price target for Myriad Genetics has shifted lower into a $6 to $7 range as analysts factor in updated sector models, reiterated 2026 guidance, and the need for clearer progress on the company’s turnaround and profitability before becoming more constructive. Analyst Commentary Recent research updates show a clear tilt toward caution, with several bearish analysts trimming their valuation ranges for Myriad Genetics and keeping ratings in the middle of the scale rather than moving to a more positive stance.Narrative Update • Mar 06
MYGN: Turnaround Execution And 2026 Pipeline Milestones Will Drive Bearish Outlook
Analysts have trimmed their price targets on Myriad Genetics to a range of about $6 to $7, reflecting more cautious assumptions on growth and profitability even as they acknowledge recent results and the company’s ongoing turnaround efforts. Analyst Commentary Recent research updates show bearish analysts trimming price targets on Myriad Genetics into a tighter band around $6 to $7, signaling a more cautious stance on the stock even as they acknowledge operational progress.Narrative Update • Feb 19
MYGN: Rebased Outlook Weighs Execution Risks Against Upcoming MRD Commercialization Potential
Analysts have adjusted their outlook on Myriad Genetics, trimming the average price target to $7 from $9. They have also updated their assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E based on recent diagnostics sector research and expectations for solid results and 2026 guidance.Analysis Article • Feb 13
Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 27% in the...Narrative Update • Feb 05
MYGN: Sector Fundamentals And New Diagnostics Partnerships Will Support A More Constructive Outlook
Analysts have lowered their price target on Myriad Genetics to $7 from $9, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, while still expecting solid diagnostics sector results and 2026 outlooks. Analyst Commentary Recent research on Myriad Genetics focuses on how the updated $7 price target lines up with expectations for the broader diagnostics group, where analysts still see solid sector results and 2026 outlooks supported by what they describe as strong fundamentals.Analysis Article • Feb 04
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrative Update • Jan 22
MYGN: Sector Strength And Expanded Cancer Testing Will Support Future Upside
Narrative Update Analysts have adjusted their view on Myriad Genetics, reflected in a higher fair value estimate from $14.33 to $16.06 as they weigh mixed price target moves in recent research and slightly different assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Myriad Genetics presents a mixed but informative picture, with some caution on price targets alongside more constructive adjustments that support the updated fair value estimate.Narrative Update • Jan 08
MYGN: Sector Strength And New Partnerships Will Support A More Constructive Outlook
Narrative Update The analyst price target for Myriad Genetics has shifted modestly lower, with a blended change of roughly $1 across recent moves to $7 and $8. Analysts are factoring in updated diagnostics sector expectations and revising their fair value estimates and P/E outlooks for the company.Narrative Update • Dec 24
MYGN: Rising Margin Visibility Will Support A More Constructive Bullish Outlook
Analysts have raised their price target on Myriad Genetics shares from $6.00 to $8.00, reflecting modest improvements in long term profit margin expectations and valuation assumptions, while maintaining a neutral overall outlook. Analyst Commentary Analyst commentary around the revised price target highlights a generally balanced view, with recognition of incremental progress offset by lingering execution and profitability concerns.Narrative Update • Dec 10
MYGN: Improved Earnings Visibility Will Shape Bullish Outlook
Analysts have modestly raised their price target on Myriad Genetics to $8 from $6, reflecting a slightly higher fair value estimate supported by improved forward price to earnings assumptions and a marginally higher discount rate that still preserves cautious revenue growth expectations. Analyst Commentary Analyst sentiment around Myriad Genetics remains balanced, with the higher price target reflecting modest improvements in forward expectations rather than a decisive shift in outlook.Narrative Update • Nov 26
MYGN: Breast Cancer Risk Collaboration And Margin Gains Will Shape Outlook
Narrative Update on Myriad Genetics Analysts have raised their price target for Myriad Genetics from $6 to $8, citing improved profit margins and modest revenue growth as key drivers for the upward revision. Analyst Commentary Analyst opinions about Myriad Genetics reflect a mix of optimism regarding the company's recent performance and continued caution around potential challenges.Narrative Update • Nov 12
MYGN: Expanded Cancer Testing Is Expected To Drive Future Gains
Narrative Update on Myriad Genetics Analysts have increased their price target for Myriad Genetics from $6 to $8. This adjustment reflects revised expectations based on updates to fair value assessments, discount rates, and future earnings metrics.Narrative Update • Oct 29
Adding Cancer Test Capabilities And Mental Health Data Will Support Long-Term Progress
Analysts have slightly raised their price target for Myriad Genetics to approximately $7.95 from $7.77 per share. They cited modest improvements in expected profit margins and updated assumptions around discount rates.Narrative Update • Oct 14
Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach
Analysts have adjusted their price target for Myriad Genetics upward from $7.38 to $7.77, citing minor improvements in profit margin and future price-to-earnings expectations, even though revenue growth projections have been slightly reduced. What's in the News Myriad Genetics has formed a strategic partnership with SOPHiA GENETICS to develop and globally deploy a liquid biopsy companion diagnostic test for pharmaceutical companies, leveraging both companies' expertise and international networks (Strategic Alliances).Analysis Article • Sep 30
Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Key Insights Myriad Genetics' estimated fair value is US$8.13 based on 2 Stage Free Cash Flow to Equity Myriad...Analysis Article • Aug 17
Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:MYGN 1 Year Share Price vs Fair Value Explore Myriad Genetics's Fair Values from the Community and select...Analysis Article • Jun 25
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares would be relieved that the share price has rebounded 29% in...Analysis Article • May 09
Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 48% in the...
New Narrative • Mar 24
PATHOMIQ AI Partnership Will Expand Oncology And Women's Health
Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.Analysis Article • Mar 16
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%
Myriad Genetics, Inc. ( NASDAQ:MYGN ) shareholders that were waiting for something to happen have been dealt a blow...Analysis Article • Feb 26
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results
There's been a notable change in appetite for Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares in the week since its annual...Shareholder Returns
| MYGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.0% | 0.09% | -0.7% |
| 1Y | 29.8% | 31.4% | 15.3% |
Return vs Industry: MYGN underperformed the US Biotechs industry which returned 31.4% over the past year.
Return vs Market: MYGN exceeded the US Market which returned 15.3% over the past year.
Price Volatility
| MYGN volatility | |
|---|---|
| MYGN Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MYGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MYGN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,700 | Sam Raha | www.myriad.com |
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Myriad Genetics, Inc. Fundamentals Summary
| MYGN fundamental statistics | |
|---|---|
| Market cap | US$514.74m |
| Earnings (TTM) | -US$399.90m |
| Revenue (TTM) | US$829.00m |
0.6x
P/S Ratio-1.3x
P/E RatioIs MYGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYGN income statement (TTM) | |
|---|---|
| Revenue | US$829.00m |
| Cost of Revenue | US$249.00m |
| Gross Profit | US$580.00m |
| Other Expenses | US$979.90m |
| Earnings | -US$399.90m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | -4.23 |
| Gross Margin | 69.96% |
| Net Profit Margin | -48.24% |
| Debt/Equity Ratio | 35.7% |
How did MYGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/28 21:37 |
| End of Day Share Price | 2026/07/28 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Myriad Genetics, Inc. is covered by 36 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |